bottom line overweight rate ia reflect view
iqv combin data technolog research asset
enabl acceler sale growth continu expand total
address market iqv revis guidanc
mix implic thesi
better result guidanc see covid impact
report better result compar estim
street consensu manag also provid full-year
guidanc well estim impli
sever sale declin vs
assumpt respect ds segment
impact busi global site
current access see larg impact ta
csm segment expect total busi
recurring/licensed-bas remain flat remain
see disrupt fluctuat next quarter
compani data secur llc estim reuter
adj acquisit integr relat expens restructur relat charg
stock-bas comp one time impact
adjust acquisit integr relat expens restructur relat
charg stock-bas comp one time impact
lever pull situat worsen provid
guidanc manag use china roadmap assum
busi activ begin recov site return
function begin assum
second wave covid guidanc covid impact
materi believ compani adopt aggress
cost cut activ mitig impact broader
program reserv liquid
model updat reduc estim
 note herein rais
target price base
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
period end incom expens expens earn loss unconsolid incom excl incom non-control incom share share ep dilut excl incl stock-bas sale growth margin gross excl acquir intang adj cash flowoperar cash cash organ servic revenu growth fye organ total revenu growth account onwardssourc secur llc estim compani report
price target
valuat ebitda estim multipl consist
peer group median risk includ disrupt merger integr cancel delay
reduc spend due pharma econom weak pipelin repriorit compound failur
rise interest rate sale privat equiti sponsor
brought togeth power data softwar consult former im busi
abil run outsourc clinic trail quintil growth still feel effect slower
quintil book restructur integr engag busi expect re-acceler
iqvia largest contract research organ largest data provid pharma compani
